Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Invest New Drugs. 2015 Dec 14;34(2):168–175. doi: 10.1007/s10637-015-0314-7

Table 6.

Summary pharmacokinetics parameters of selumetinib on day 1 of cycle 1

Dose level 1 and 2 combined (N=10) Dose level 3 (N=22a) p-value
Cmax (ng/mL) 1212 (CV 0.24) 1504 (CV 0.40) 0.08
AUC 0-∞ (ng/mL × hr) 3448 (CV 0.17) 5200 (CV 0.58) 0.01
Log (Cmax (ng/mL) – dose normalized 3.19 ± 0.23 3.00 ± 0.43 0.20
Log(AUC 0-∞ (ng/mL × hr) – dose normalized 4.23 ± 0.17 4.24 ± 0.54 0.97

Data are shown as geometric mean and coefficient of variation (CV) for Cmax and AUC, and as mean ± standard deviation for log-transformed, dose normalized Cmax and AUC.

a

Includes patients at dose level 3 and the dose expansion cohort